Michelle Dalton, ELS

Articles by Michelle Dalton, ELS

Antibiotic resistance against fluoroquinolones is increasing, and that may adversely impact patients with retinal disorders. The introduction of intravitreal injections (IVT) to treat retinal diseases has increased from about 1 million in 2007 to an expected 6 million in 2016 (up from only 4,000 in 2001).

A topical treatment that breaks apart disulfide bonds between crystalline lens proteins was shown to increase accommodative amplitude and improve near visual acuity in a randomized, placebo-controlled clinical trial.

High-level evidence supports the use of anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (AMD), but falls short of recommending any one agent over another in terms of efficacy or safety, said Paul Sternberg Jr., MD.

An extended-release therapy that encapsulates travoprost in an intracameral implant showed a statistically significant and clinically meaningful reduction in IOP with results comparable to topical once-daily travoprost ophthalmic solution, said Tom R. Walters, MD, Texan Eye, Austin.

Lines continue to blur as to what constitutes refractive surgery, and likely will continue to blur well into the future. Multiple compounds-phenylephrine and ketorolac 1%/0.3%, (Omidria, Omeros) and the “Dropless” line (Tri-Moxi/Tri-moxi-Vanc, Imprimis Pharmaceuticals)-are designed for use in cataract surgery, but their goal is to improve refractive outcomes. 2015 was the year they started to get some serious attention.

Ultra-widefield (UWF) imaging provides clinicians a much broader view of the retinal periphery. The Optos California uses multiple UWF imaging modalities, including color, autofluorescence, fluorescein angiography (FA), and indocyanine green (ICG) angiography in a 200° picture.

Latest Updated Articles